New Rochelle, NY, January 4, 2018--Acute chest syndrome (ACS), a potentially severe lung complication of sickle cell disease, increases a child's risk of respiratory failure, chronic lung disease, and prolonged hospitalization if not recognized early and treated effectively. Risk factors of ACS and effective preventive and therapeutic strategies to prevent recurrent episodes in children with sickle cell disease are presented in a new article published in Pediatric Allergy, Immunology, and Pulmonology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Pediatric Allergy, Immunology, and Pulmonology website.
In "Acute Chest Syndrome in Children with Sickle Cell Disease," coauthors Shilpa Jain, Women and Children's Hospital of Buffalo and Hemophilia Center of Western New York, Buffalo, and Nitya Bakshi and Lakshmanan Krishnamurti, Children's Healthcare of Atlanta, GA, examine the multiple factors that can contribute to a child's increased risk of ACS and proposed mechanisms by which ACS may develop. The researchers also provide a comprehensive review of the clinical features of ACS in this patient population, preventive approaches including the use of hydroxurea, and what is needed to achieve a prompt diagnosis. Effective therapies, pain control and when to consider the use of bronchodilators are other important topics discussed.
"Management of acute chest syndrome is a major challenge for physicians and other healthcare providers caring for children with sickle cell disease. Not only can episodes recur but damage from repeated episodes can lead to pulmonary infarcts, fibrosis and deterioration in lung function." says Pediatric Allergy, Immunology, and Pulmonology Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, Stony Brook University School of Medicine. "It is not only important to know how to recognize and treat an acute episode but to be able to implement long term management strategies to try and prevent future episodes."
About the Journal
Pediatric Allergy, Immunology, and Pulmonology is a quarterly, peer-reviewed journal published online with open access options and in print that synthesizes the pulmonary, allergy, and immunology communities in the advancement of the respiratory health of children. Led by Editor-in-Chief Mary Cataletto, MD, Professor of Clinical Pediatrics, State University of New York at Stony Brook, the Journal provides comprehensive coverage to further the understanding and optimize the treatment of some of the most common and costly chronic illnesses in children. It includes original translational, clinical, and epidemiologic research; public health, quality improvement, and case control studies; patient education research; and the latest research and standards of care for functional and genetic immune deficiencies and interstitial lung diseases. Tables of content and a sample issue may be viewed on the Pediatric Allergy, Immunology, and Pulmonology website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Breastfeeding Medicine, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publisher's website.